Although intravitreal anti–vascular endothelial growth factor has greatly improved the management of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration,1- 4 little is known regarding the effects in more advanced stages associated with low visual acuity. We designed a randomized clinical trial to address this subject.
Correspondence: Dr Iacono, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Via Olgettina, 60, 20132, Milano, Italy (firstname.lastname@example.org).
Author Contributions: Dr Iacono had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Trial Registration: clinicaltrials.gov Identifier: NCT01327222
Previous Presentation: This paper was presented in part at the 34th Annual Meeting of the Macula Society; March 10, 2011; Boca Raton, Florida.